The Form 144 filing by an officer signals potential insider selling. Given the small relative size (0.07% of market cap), the direct impact is limited, but it may indicate insider sentiment. Monitor for actual Form 4 filings to confirm the sale and watch for any subsequent insider selling patterns.
NMRA drugs
NMRA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $1.64entry
- T+1 · 3mo ago 0.00%α −0.21% · $1.64
- T+5 · 3mo ago −8.54%α −8.34% · $1.50
- T+20 · 2mo ago −52.85%α −51.54% · $0.7732
- T+60 · 6d ago −71.16%α −70.16% · $0.4730
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Aurora Daljit Singh, an officer of Neumora Therapeutics, filed a Form 144 notice of intent to sell 146,706 shares of common stock, with an approximate market value of $220,135. The shares were acquired through the exercise of employee stock options and vesting of restricted stock units. This filing signals the insider's intent to sell, though the sale may not be executed.
Key Facts
- Officer Aurora Daljit Singh filed Form 144 to sell 146,706 shares.
- Estimated market value of the proposed sale is $220,135.
- Shares were acquired through exercise of employee stock options and vesting of RSUs.
- The filing date is August 17, 2026.
- The company has a market cap of $296M.
Financial Impact
Proposed sale of 146,706 shares valued at approximately $220,135, representing about 0.07% of the company's $296M market cap.
Risk Factors
- Insider selling could signal lack of confidence in near-term prospects.
- The sale may not be executed; Form 144 is only an intent to sell.
- Biotech sector volatility could amplify any negative sentiment from insider selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000398 |
| Document: 0001964306-26-000398-index.html | 0001964306-26-000398 |
| Document: 0001964306-26-000398.txt | 0001964306-26-000398 |
Track record
14 reports on NMRA
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
- Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
- Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
- Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
- Aug 17, 202613w ago 144 Bearish 5/10 Viewing Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 4/10 No price data
- Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
- Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
- Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers